@article{7b539af2628c40d9ae31accb4986cb2c,
title = "Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives",
abstract = "Despite robust evidence of neurocognitive dysfunction in psychotic patients, the degree of similarity in cognitive architecture across psychotic disorders and among their respective first-degree relatives is not well delineated. The present study examined the latent factor structure of the Brief Assessment of Cognition in Schizophrenia (BACS) neuropsychological battery. Analyses were conducted on 783 psychosis spectrum probands (schizophrenia, schizoaffective, psychotic bipolar), 887 of their first-degree relatives, and 396 non-psychiatric controls from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium. Exploratory factor analysis of BACS subtest scores indicated a single-factor solution that was similar across all groups and provided the best overall data fit in confirmatory analyses. Correlations between the standard BACS composite score and the sum of subscale scores weighted by their loadings on this unitary factor were very high in all groups (r ≥ .99). Thus, the BACS assesses a similar unitary cognitive construct in probands with different psychotic disorders, in their first-degree relatives, and in healthy controls, and this factor is well measured by the test's standard composite score.",
keywords = "Brief Assessment of Cognition in Schizophrenia, Factor analysis, First-degree relatives, Psychosis",
author = "Hochberger, {W. C.} and Hill, {S. K.} and Nelson, {C. L.M.} and Reilly, {J. L.} and Keefe, {R. S.E.} and Pearlson, {G. D.} and Keshavan, {M. S.} and Tamminga, {C. A.} and Clementz, {B. A.} and Sweeney, {J. A.}",
note = "Funding Information: This study was supported in part by NIMH grants MH078113 , MH077945 , MH077852 , MH077851 , MH077862 , MH072767 , and MH083888 . Funding Information: Dr. Tamminga has received support from Intracellular Therapies (ITI, Inc.), PureTech Ventrues, Eli Lilly Pharmaceuticles, Sunovion, Astellas, Merck (ad hoc consulting), International Congress on Schizophrenia Research (unpaid volunteer), NAMI (unpaid volunteer), American Psychiatric Association (Deputy Editor), and Finnegan Henderson Farabow Garrett & Dunner, LLP. Dr. Keefe has received investigator-initiated support from the Department of Veteran's Affair, Feinstein Institute for Medical Research, GlaxoSmithKline, National Institute of Mental Health, Novartis, Psychogenics, Research Foundation for Mental Hygiene, Inc., and the Singapore National Medical Research Council. Dr. Keefe has received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Astellas, Asubio, BMS, Roche, and Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept. Dr. Keefe is a shareholder in Sengenix and NeuroCog Trials, Inc. and receives royalties from the BACS testing battery and the MATRICS Battery (BACS Symbol Coding). Dr. Bishop has received research support from Ortho-McNeil Janssen. Dr. Keshavan has received support from Sunovion and GlaxoSmithKline. Dr. Sweeney has received support from Takeda, BMS, Roche, and Eli Lilly and research funding from Janssen. The other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2015 Elsevier B.V..",
year = "2016",
doi = "10.1016/j.schres.2015.11.022",
language = "English (US)",
volume = "170",
pages = "156--161",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",
}